ArticleCancer immunology, immunotherapy : CII2009
Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.
Article in Cancer immunology, immunotherapy : CII, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 59 citations in OpenAlex.
- Numb and NumbL inhibit melanoma tumor growth by influencing the immune microenvironment.BMC cancer · 2024Article
- Promotion of gastric tumor initiating cells in a 3D collagen gel culture model via YBX1/SPP1/NF-κB signaling.Cancer cell international · 2021Article
- Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8 + and regulatory FOXP3 + cells tumor-associated infiltrate and other prognostic factors.Virchows Archiv : an international journal of pathology · 2021Article
- PODXL2 maintains cellular stemness and promotes breast cancer development through the Rac1/Akt pathway.International journal of medical sciences · 2020Article
- Phyto-Immunotherapy, a Complementary Therapeutic Option to Decrease Metastasis and Attack Breast Cancer Stem Cells.Frontiers in oncology · 2020Review
- Evodiamine Eliminates Colon Cancer Stem Cells via Suppressing Notch and Wnt Signaling.Molecules (Basel, Switzerland) · 2019Article
- Inhibition of the Numb/Notch signaling pathway increases radiation sensitivity in human nasopharyngeal carcinoma cells.The Kaohsiung journal of medical sciences · 2019Article
- Cancer stem cells as targets for immunotherapy.Immunology · 2018Review
- A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.Oncotarget · 2016Article
- Immune targeting of cancer stem cells in gastrointestinal oncology.Journal of gastrointestinal oncology · 2016Review
- Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells.Frontiers in pharmacology · 2016Review
- Role of Numb expression and nuclear translocation in endometrial cancer.Oncology letters · 2015Article
- Immunotargeting of cancer stem cells.Contemporary oncology (Poznan, Poland) · 2015Review
- Necrosis and apoptosis in Trichinella spiralis-mediated tumour reduction.Central-European journal of immunology · 2015Article
- Breast cancer stem cells and the immune system: promotion, evasion and therapy.Journal of mammary gland biology and neoplasia · 2014Review
- The immune system and inflammation in breast cancer.Molecular and cellular endocrinology · 2014Review
- Therapeutic cancer vaccines.Advances in cancer research · 2014Review
- Interplay of Stem Cell Characteristics, EMT, and Microtentacles in Circulating Breast Tumor Cells.Cancers · 2013Article
- Immunotherapy of radioresistant mammary tumors with early metastasis using molecular chaperone vaccines combined with ionizing radiation.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Therapeutic cancer vaccines: current status and moving forward.Journal of the National Cancer Institute · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Cancer stem cells (CSC) are resistant to chemo- and radiotherapy. To eliminate cells with phenotypic markers of CSC-like we characterized: (1) expression of CD44, CD24, CD133 and MIC-A/B (NKG2 receptors) in breast (MCF7) and ovarian (SK-OV-3) cells resistant to gemcitabine (GEM), paclitaxel (PTX) and 5-fluorouracil (5-FU) and (2) their elimination by Numb- and Notch-peptide activated CTL. The number of cells in all populations with the luminal CSC phenotype [epithelial specific antigen(+) (ESA) CD44(hi) CD24(lo), CD44(hi) CD133(+), and CD133(+) CD24(lo)] increased in drug-resistant MCF7 and SK-OV-3 cells. Similarly, the number of cells with expressed MIC-A/B increased 4 times in drug-resistant tumor cells compared with drug-sensitive cells. GEM(Res) MCF7 cells had lower levels of the Notch-1-extracellular domain (NECD) and Notch trans-membrane intracellular domain (TMIC) than GEM(Sens) MCF7. The levels of Numb, and Numb-L-[P]-Ser(265) were similar in GEM(Res) and GEM(Sens) MCF7 cells. Only the levels of Numb-L (long)-Ser(295) decreased slightly. This finding suggests that Notch-1 cleavage to TMIC is inhibited in GEM(Res) MCF7 cells. PBMC activated by natural immunogenic peptides Notch-1 (2112-2120) and Numb-1 (87-95) eliminated NICD(positive), CD24(hi) CD24(lo) MCF7 cells. It is likely that the immunogenic Numb-1 peptide in MCF7 cells originated from Numb, [P]-lated by an unknown kinase, because staurosporine but not wortmannin and MAPK-inhibitors decreased peptide presentation. Numb and Notch are antagonistic proteins which degrade each other to stop and activate cell proliferation, respectively. Their peptides are presented alternatively. Targeting both antagonistic proteins should be useful to prevent metastases in patients whose tumors are resistant to conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.